Iterum Therapeutics (ITRM) Income towards Parent Company (2017 - 2022)
Historic Income towards Parent Company for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to -$5.1 million.
- Iterum Therapeutics' Income towards Parent Company fell 2171.21% to -$5.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$44.4 million, marking a year-over-year increase of 5147.22%. This contributed to the annual value of -$25.1 million for FY2024, which is 3731.86% up from last year.
- As of Q4 2022, Iterum Therapeutics' Income towards Parent Company stood at -$5.1 million, which was down 2171.21% from -$29.1 million recorded in Q3 2022.
- Iterum Therapeutics' 5-year Income towards Parent Company high stood at $7.8 million for Q2 2021, and its period low was -$98.9 million during Q1 2021.
- In the last 5 years, Iterum Therapeutics' Income towards Parent Company had a median value of -$14.1 million in 2018 and averaged -$18.5 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 16227.94% in 2021, then tumbled by 87810.75% in 2022.
- Over the past 5 years, Iterum Therapeutics' Income towards Parent Company (Quarter) stood at -$24.3 million in 2018, then grew by 0.54% to -$24.1 million in 2019, then soared by 50.75% to -$11.9 million in 2020, then soared by 64.8% to -$4.2 million in 2021, then dropped by 21.71% to -$5.1 million in 2022.
- Its Income towards Parent Company was -$5.1 million in Q4 2022, compared to -$29.1 million in Q3 2022 and -$6.7 million in Q2 2022.